Qnexa phentermine/topiramate: Extension study data

Top-line data from the double-blind, 52-week SEQUEL (OB-305) extension study of the 56-week Phase III CONQUER (OB-303) trial in 675 obese or overweight patients showed that both doses of once-daily oral Qnexa phentermine/topiramate (7.5 mg/46 mg or 15 mg/92 mg) met the co-primary endpoints of mean percentage weight loss from baseline and percentage of subjects achieving >=5% ,

Read the full 588 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE